September 8, 2022
Bioxcellerator, located in Medellin, Colombia, treats patients from around the world with its unique, expanded MSC therapy from Wharton’s Jelly. They have been tracking their patients’ outcomes for over a year, and have granted us permission to share the following early and RWE derived insights:
These follow up data are crucial to helping Bioxcellerator better understand their patients’ outcomes, communicate those expected outcomes to new patients, and achieve more predictable outcomes for all. Upcoming insights will include identifying the patient criteria more commonly associated with non-responders, as well as obtaining statistically significant 12 month follow-ups.
To learn more about Bioxcellerator, click here.
September 8, 2022
Bioxcellerator, located in Medellin, Colombia, treats patients from around the world with its unique, expanded MSC therapy from Wharton’s Jelly. They have been tracking their patients’ outcomes for over a year, and have granted us permission to share the following early and RWE derived insights:
These follow up data are crucial to helping Bioxcellerator better understand their patients’ outcomes, communicate those expected outcomes to new patients, and achieve more predictable outcomes for all. Upcoming insights will include identifying the patient criteria more commonly associated with non-responders, as well as obtaining statistically significant 12 month follow-ups.
To learn more about Bioxcellerator, click here.